Tirzepatide reduces hypertension risk but increases hypotension risk compared to semaglutide in T2DM and obesityTirzepatide shows lower risk of high blood pressure than semaglutide

This meta-analysis evaluated the safety profiles of two prominent GLP-1 receptor and GIP receptor agonists, tirzepatide and semaglutide, in a large cohort of 47,332 patients diagnosed with Type 2 Diabetes Mellitus or obesity. The study specifically focused on treatment-emergent adverse events (TEAEs) related to blood pressure, including both hypertension and hypotension, to differentiate the cardiovascular safety profiles of these medications.

The primary analysis compared tirzepatide directly against semaglutide. For patients treated with tirzepatide, the data revealed a significantly lower risk of hypertension-related events compared to those receiving semaglutide (RR = 0.40; 95% CI [0.26-0.60]; p < 0.001). Conversely, tirzepatide was associated with an increased risk of hypotension-related events when compared to semaglutide (RR = 2.45; 95% CI [1.35-4.45]; p = 0.003).

A secondary analysis focused on the impact of dosage on safety outcomes for tirzepatide. The data indicated a dose-dependent risk of hypotension, where patients receiving high doses of tirzepatide showed an even higher risk of hypotension compared to semaglutide (RR = 2.58; 95% CI [1.38-4.81]; p = 0.003). These findings suggest that while the drug may have a favorable profile regarding hypertension, its impact on blood pressure stability is dose-sensitive.

In contrast, semaglutide demonstrated a neutral safety profile regarding both conditions when compared to tirzepatide. There was no significant association for hypertension-related events in the semaglutide group (RR = 0.81; 95% CI [0.57-1.15]; p = 0.233). Similarly, there was no significant difference in hypotension-related events for patients taking semaglutide compared to those on tirzepatide (RR = 1.39; 95% CI [0.81-2.36]; p = 0.232).

These results provide a nuanced comparison of the two agents. While both are effective for weight management and glycemic control, their effects on blood pressure stability differ. Tirzepatide appears to offer a protective signal against hypertension but carries a higher risk of hypotension, particularly in high-dose regimens. Semaglutide maintains a consistent profile without significant deviations in blood pressure outcomes relative to the tirzepatide cohort.

Methodological limitations were not reported, and specific details regarding study settings or follow-up durations are unavailable. However, the large sample size of 47,332 patients provides a robust basis for these associations. Clinicians should consider these findings when selecting between tirzepatide and semaglutide for patients with existing blood pressure sensitivities. Specifically, clinicians must weigh the lower risk of hypertension against the increased, dose-dependent risk of hypotension associated with tirzepatide.

Questions remain regarding the specific clinical drivers behind the observed hypotension in high-dose tirzepatide groups and whether these events lead to significant clinical sequelae or treatment discontinuation. Further investigation into the mechanism of this dose-dependent effect is necessary to optimize titration protocols for patients at risk of hypotension.